Azithromycin

Antibiotic with anti-inflammatory properties

Phase of research

FDA-approved for Cystic Fibrosis

How it helps

Anti-Infective

General information

Azithromycin is a broad-spectrum antibiotic. It is sold under the name e.g., Zithromax® and was approved in the USA in 1996. It is used to treat respiratory, enteric and genitourinary infections. In relation to cystic fibrosis, our AIM tool found the data that azithromycin can reduce the risk of pulmonary exacerbation and improve clinically relevant endpoints in patients chronically infected with Pseudomonas aeruginosa.

Azithromycin on PubChem
Azithromycin on DrugBank
Azithromycin on Wikipedia

Synonyms

N/A

Marketed as

Zithromax - prescribing information

Dietary sources

N/A

Structure image not available

C₃₈H₇₂N₂O₁₂

Drug-Mutation Relation

results for 1677delTA / G542X

See all data on Azithromycin

Treats

Mutation	Link	Tested on	Impact factor
General effect	Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial.	humans	16.49
General effect	Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.	humans	30.01
General effect	Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.	humans	21.46
General effect	Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial.	humans	6.06

Does not treat

Mutation	Link	Tested on	Impact factor	Notes